From Washington to Wall Street, it's a crazy time for biotech. But as Ultragenyx Pharmaceutical Inc. celebrates its 15th ...

A Cambridge biotech has taken over development of a Roche rare disease drug, Cue Biopharma signed a deal with Boehringer ...

JelloX Biotech. Inc, a Taiwan-based cancer pathology startup, will establish a U.S. research base in Phoenix, according to a ...

A 1975 meeting at the Asilomar Conference Center in Pacific Grove, California, shaped a new safety regime for recombinant DNA ...

CERo Therapeutics (CERO) announces the allowance of two patent applications submitted to the U.S. Patent and Trademark Office, USPTO, which ...

CERo Therapeutics (CERO) announces its first clinical trial site for the Company’s Phase 1 clinical trial of CER-1236. The trial is focused on ...

Biotech companies create drugs from living organisms, requiring a BLA for FDA approval. Pharma companies develop drugs from chemicals, needing an NDA for FDA approval. Many firms blend biotech and ...

No sector is left unchanged by the power of AI and digital modeling, and Biotech is no exception. This is because biology is by far the most “messy” of hard sciences. Chemistry or physics can deal ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

In this interview Prof. Dr. Kristina Kusche-Vihrog speaks about the nanomechanics of living cells and their implications for cardiovascular disease. Molecular Devices' CellXpress AI streamlines ...